This is a working overview of Copper tripeptide, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-12-30 and is reviewed periodically as new material appears.
Commercial products list GHK-Cu as copper tripeptide-1, a cosmetic ingredient. Formulators value its blue color and water solubility, which allow incorporation into serums, creams, and masks. Regulatory treatment varies: in the United States it appears in cosmetics, while some jurisdictions classify certain claims as drug-like. The compound is not an approved drug for any indication. Studies continue to examine its effects on skin, hair, and wound repair, but dosage, delivery, and long-term safety questions remain open.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and copper(II). The peptide sequence consists of glycine, histidine, and lysine, and its imidazole and amino groups provide binding sites for the metal ion. In the complex, copper is held through nitrogen donors from the histidine side chain, the N-terminal amine, and deprotonated amide nitrogens. The resulting compound is intensely blue and water-soluble. It occurs naturally in human plasma, saliva, and urine at low concentrations.
The peptide sequence places a histidine in the middle, and this residue dominates metal binding. Copper(II) coordinates through the imidazole nitrogen of histidine and the terminal amino group, forming a stable chelate ring system. Loss of the copper ion leaves the free tripeptide, which has different solubility and reactivity. This structural detail matters because assays that measure only the peptide backbone can miss whether copper is still bound to it.
Several names circulate for the same material, which complicates literature searches. Cosmetic ingredient lists often use copper tripeptide-1, while older biochemistry papers use glycyl-L-histidyl-lysine or its abbreviation GHK. The copper complex is sometimes written as GHK-Cu(II) to make the oxidation state explicit. Terminology is not fully standardized, so matching a compound across sources requires attention to the exact sequence, the counterion, and the stated copper content. Reviews that compare studies must account for these naming differences before drawing conclusions.
GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine, a short sequence of three amino acids. The peptide was first isolated from human plasma in 1973 during research on factors that influence tissue repair in liver. Its ability to bind copper ions became a central point of interest because the metal changes the peptide's chemistry and its behaviour in laboratory systems. Today the compound appears in cosmetic formulations, cell-culture studies, and biochemistry literature under several names.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Copper(II) tripeptide complex | Contains glycyl-histidyl-lysine ligand |
| Peptide sequence | Gly-His-Lys | N-terminal glycine, C-terminal lysine |
| Molecular formula | C14H22CuN6O4 | Commonly cited for the 1:1 complex |
| Appearance | Blue to blue-violet solid | Color arises from copper d-d transitions |
| Solubility | Water-soluble | Also dissolves in some polar solvents |
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide sequence is often abbreviated Gly-His-Lys, and the copper is bound through the histidine imidazole nitrogen and adjacent peptide nitrogens. The complex is frequently described as a 1:1 peptide-to-copper species. It occurs naturally in human plasma, saliva, and urine at low concentrations. Its endogenous levels have been reported to decline with age, although the precise physiological role of that change remains an open question.
Research interest in GHK-Cu centers on its ability to deliver copper and to influence cellular processes in laboratory models. In cell culture and animal studies, the complex has been linked to collagen synthesis, antioxidant enzyme activity, and expression of genes associated with tissue remodeling. These effects are not equivalent to proven clinical outcomes. The mechanisms proposed include copper transfer to cuproenzymes, modulation of growth factor signaling, and interactions with extracellular matrix components. How much of the observed activity depends on intact GHK-Cu versus free copper or free peptide is not fully resolved.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The peptide binds copper through its histidine imidazole nitrogen, its terminal amino group, and a deprotonated amide nitrogen, creating a stable chelate ring. The resulting complex carries a distinctive blue to blue-violet color, which arises from copper d-d electronic transitions. In the solid state it is usually handled as a powder, while in solution the complex can dissociate and re-form depending on pH and competing ligands. The name copper tripeptide-1 is widely used in ingredient listings.
The tripeptide was first isolated from a human plasma filtrate in 1973 during studies of tissue repair factors. Later work detected the free peptide and its copper complex in saliva, urine, and wound fluid, suggesting a natural role in tissue remodeling. Plasma concentrations reported in early literature decline with age, a pattern often cited in discussions of skin aging. Whether these endogenous levels are directly functional or largely incidental remains an open question. The peptide sequence is conserved across mammalian species.
Material described in research and cosmetic supply chains is typically a synthetic peptide supplied as a lyophilized powder. Purity is commonly reported through chromatographic separation, often at 95 percent or higher, while copper content is confirmed by separate elemental analysis. Batch variation in color and solubility can reflect residual counter-ions, moisture, or partial oxidation of the peptide. Because the complex is not a single regulatory entity, specifications differ between suppliers and are not standardized internationally.
GHK-Cu is a coordination complex formed between the tripeptide glycyl-L-histidyl-lysine and a copper(II) ion. The peptide sequence is conventionally written as Gly-His-Lys, abbreviated GHK. Copper binds through the imidazole nitrogen of histidine, the alpha-amino group, and a deprotonated amide nitrogen, producing a square-planar geometry. The complex carries a net positive charge near physiological pH and is intensely blue in aqueous solution. The metal-free peptide is often written simply as GHK, while the copper-bound form is written GHK-Cu.
The compound was first isolated from human plasma by the biochemist Loren Pickart in 1973. Early work identified it as a factor that altered the behavior of cultured liver cells, and later studies linked it to connective tissue and wound-related processes. Reported plasma concentrations fall markedly between roughly age twenty and age sixty, a pattern that generated interest in copper peptide biology. Whether that decline has functional consequences remains an open question, because differences observed across age groups do not by themselves establish causation. Research interest later expanded into cosmetic and tissue-culture settings.
Adriaens, D. and Verraes, W. (1997). Ontogeny of the maxillary barbel muscles in Clarias gariepinus (Siluroidei: Clariidae), with some notes on the palatine-maxillary mechanism. Journal of Zoology (London) 241, 117–133. Bailey, D.M. , Wagner, H.J., Jamieson, A.J., Ross, M.F. and Priede, I.G. (2007) A taste of the deep-sea: The roles of gustatory and tactile searching behaviour in the grenadier fish Coryphaenoides armatus. Deep-Sea Research Part I: Oceanographic Research Papers, 54(1), pp. 99–108. (doi:10.1016/j.dsr.2006.10.005) de Freitas Barros Neto, L., Frigo, R. G., Gavilan, S. A., de Moura, S. A. B., & Lima, S. M. Q. (2020). Barbel development associated to aquatic surface respiration in Triportheus signatus (Characiformes: Triportheidae) from the semiarid Caatinga rivers. Environmental Biology of Fishes, 103(1), 89–98. https://doi.org/10.1007/s10641-019-00935-x Eakin, R. R., Eastman, J. T. and Vacchi, M. (2006). Sexual dimorphism and mental barbel structure in the South Georgia plunderfish Artedidraco mirus (Perciformes : Notothenioidei : Artedidraconidae). Polar Biology 30, 45–52. Fadaee, B., Pourkazemi, M., Tavakoli, M., Joushideh, H., Khoshghalb, M. R. B., Hosseini, M. R. and Abdulhay, H. (2006). Tagging and tracking juvenile sturgeons in shallow waters of the Caspian Sea (less than 10 m depth) using CWT (Coded Wire Tags) and barbel incision. Journal of Applied Ichthyology 22, 160–165. Fox, H. (1999). Barbels and barbel-like tentacular structures in sub-mammalian vertebrates: A review. Hydrobiologia 403, 153–193. Grover-Johnson, N. and Farbman, A. (1976).
== Research == The minimum dose (5 mg/kg) was confirmed in a clinical trial performed by HTI Bio-services, Inc. It evaluated the effective dose for the treatment of an infected dermal wound. The study included forty-eight mixed breed dogs (both male and female) with weights ranging from 14.5-24.5 kilograms. These dogs were randomly placed into treatment groups. Once wounds were created, the dogs were inoculated with culture both containing both Escherichia coli and Klebsiella pneumoniae. Pertinent observations and measurements were then taken and tabulated. Culture scores were significantly reduced, confirming 5 mg/kg to be an effective dose. Clinical field trials were also performed to evaluate both the efficacy and safety of difloxacin tablets. Clinical signs of bacterial infections were defined in a protocol. Dogs who presented to investigators with these signs were admitted into the study. In total, eighteen veterinarians located in four different geographical areas of the U.S. (Southeast, Midwest, Northwest, and West) conducted these clinical efficacy and safety evaluations.
Niels Lund Chrestensen (9 August 1940 – 16 August 2025) was a German businessman and plant breeder. He was a recipient of the Order of Merit of the Federal Republic of Germany (1999). Chrestensen died on 16 August 2025, in Erfurt, Thuringia, at the age of 85.
=== Clinical trials === In addition to the increased production at the Dunn School, commercial production from a pilot plant established by Imperial Chemical Industries became available in January 1942, and Kembel, Bishop and Company delivered its first batch of 200 imperial gallons (910 L) on 11 September. Florey conducted a second series of clinical trials. Ethel was placed in charge, but while Florey was a consulting pathologist at Oxford hospitals and therefore entitled to use their wards and services, Ethel, to his annoyance, was accredited merely as his assistant. Doctors tended to refer patients to the trial who were in desperate circumstances rather than those who were the most suitable candidates for treatment, but when penicillin did succeed anyway, confidence in its efficacy rose. Harry Lambert, a friend of Fleming's dying from a meningococcal infection, became the twelfth case on 5 August 1942. He survived, but someone at St. Mary's Hospital leaked the result to the press, resulting in an editorial in The Times on 27 August. Florey was appalled; this could only create a public demand for penicillin when all available supplies were needed for the clinical trials. On 25 September, Florey met with Sir Cecil McAlpine Weir, the Director-General of Equipment and Stores at the Ministry of Supply, who promised overriding priority for the mass production of penicillin. Ethel and Howard Florey published the results of clinical trials of 187 cases of treatment with penicillin in The Lancet on 27 March 1943.
Sources: en.wikipedia.org
=== Hormone excess === If there is an excess of growth hormone, it is usually because of over-secretion of somatotrope cells in the anterior pituitary gland. A significant amount of excess somatotrope secretion before puberty or before the end of new bone tissue growth can lead to gigantism, a disease that causes excess growth of body (e.g. being over 7 ft. tall) and unusually long limbs. An excess of secretion of growth hormone after puberty can lead to acromegaly. This is a disease that causes abnormal growth in the hands, head, jaw, and tongue. Some symptoms associated with acromegaly include heavy sweating, oily skin, improper processing of sugars in the diet (diabetes), high blood pressure, increased calcium in urine and swelling of the thyroid gland and arthritis.
=== Appointment === As per Art. 316, the chairman and other members of the Union Public Service Commission shall be appointed by the president. In case the office of the chairman becomes vacant, the duties shall be performed by one of the other members of the Commission at the appointment of the President. Also, nearly half of the members of the Commission shall be persons who, at the dates of their respective appointments, have held office for at least ten years either under the Government of India or under the Government of a State. A member of the Union Public Service Commission shall hold office for a term of six years from the date on which they enter upon the office or until they attain the age of sixty-five years, whichever is earlier. Under Art 318, the President is empowered to determine the number of members of the commission and their conditions of service. As per Art 319, a person who holds office as chairman shall, on the expiration of the term of office, be ineligible for re-appointment to that office. But, a member other than the chairman of the Union Public Service Commission shall be eligible for appointment as the chairman of the Union Public Service Commission, or as the chairman of a State Public Service Commission, but not for any other employment either under the Government of India or under the Government of a State. Also, the chairman of a State Public Service Commission shall be eligible for appointment as the chairman or any other member of the Union Public Service Commission.
==== Cholestasis ==== Liver injury leads to impairment of bile flow and cases are predominated by itching and jaundice. Histology may show inflammation (cholestatic hepatitis) or it can be bland (without any parenchymal inflammation). On rare occasions, it can produce features similar to primary biliary cirrhosis due to progressive destruction of small bile ducts (vanishing duct syndrome).
Sources: en.wikipedia.org
GHK is the free tripeptide, while GHK-Cu includes a bound copper(II) ion. The copper complex is the form most often studied for skin and wound-related activity. The two names are sometimes used interchangeably in product labeling, but they refer to distinct chemical species.
Yes, it is found in human plasma, saliva, and urine. Its concentration in plasma tends to decrease with age. This natural presence is one reason researchers have investigated its role in tissue maintenance.
No, GHK-Cu is not an approved drug in major markets. It is widely used as a cosmetic ingredient, where it is listed under names such as copper tripeptide-1. Any therapeutic claims would require separate regulatory review.
The peptide is glycyl-L-histidyl-L-lysine, a three-amino-acid sequence commonly abbreviated GHK. It binds a single copper(II) ion under typical laboratory conditions. The free peptide and the copper complex are separate chemical species with different properties.